Condensed Statements of Operations - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses
Research and development		$ 2,747	$ 2,594	$ 8,177	$ 7,163
General and administrative		2,975	1,257	9,504	4,180
Long-lived assets impairment		1,614		1,614	0
Right of use asset impairment		322		322	0
Total operating expenses		7,658	3,851	19,617	11,343
Other income
Interest income		80	1	116	3
Derivative gain		1,167	222	5,384	489
Total other income		1,247	223	5,500	492
Net loss		$ (6,411)	$ (3,628)	$ (14,117)	$ (10,851)
Net loss per common share: Basic	[1]	$ (0.43)	$ (0.27)	$ (0.94)	$ (0.82)
Net loss per common share: Diluted	[1]	$ (0.50)	$ (0.29)	$ (1.29)	$ (0.86)
Weighted average number of common shares outstanding: Basic	[1]	15,072,392	13,361,292	15,072,307	13,156,469
Weighted average number of common shares outstanding: Diluted	[1]	15,072,392	13,437,543	15,072,307	13,238,404

[1] Net loss per common share and weighted average number of common shares outstanding for all periods shown have been retroactively adjusted to reflect the 15-to-1 reverse stock split effected November 9, 2022.